Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Supports broader genetic testing in CVD clinics; leaves open standardization and outcome validation for routine use.
Genetics plays an important role in the pathophysiology of cardiovascular diseases, and is increasingly being integrated into clinical practice. Since 2008, both capacity and cost-efficiency of mutation screening of DNA have been increased magnificently due to the technological advancement obtained by next-generation sequencing. Hence, the discovery rate of genetic defects in cardiovascular genetics has grown rapidly and the financial threshold for gene diagnostics has been lowered, making large-scale DNA sequencing broadly accessible. In this review, the genetic variants, mutations and inheritance models are briefly introduced, after which an overview is provided of current clinical and technological applications in gene diagnostics and research for cardiovascular disease and in particular, dilated cardiomyopathy. Finally, a reflection on the future perspectives in cardiogenetics is given.
No takes yet. Share an insight, caveat, or question.
Kummeling et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: